Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Ionis Pharmaceuticals stock

IONS
US4622221004
A2ACMZ

Price

36.61
Today +/-
-0.38
Today %
-1.09 %

Ionis Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Ionis Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Ionis Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Ionis Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Ionis Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Ionis Pharmaceuticals Stock Price History

DateIonis Pharmaceuticals Price
12/13/202436.61 undefined
12/12/202437.01 undefined
12/11/202437.99 undefined
12/10/202438.26 undefined
12/9/202438.58 undefined
12/6/202438.11 undefined
12/5/202436.75 undefined
12/4/202437.15 undefined
12/3/202435.81 undefined
12/2/202436.10 undefined
11/29/202435.73 undefined
11/27/202435.90 undefined
11/26/202435.37 undefined
11/25/202435.46 undefined
11/22/202434.01 undefined
11/21/202433.94 undefined
11/20/202435.40 undefined
11/19/202433.75 undefined
11/18/202433.73 undefined
11/15/202434.34 undefined

Ionis Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ionis Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ionis Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ionis Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ionis Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ionis Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ionis Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ionis Pharmaceuticals’s growth potential.

Ionis Pharmaceuticals Revenue, EBIT and net profit per share

DateIonis Pharmaceuticals RevenueIonis Pharmaceuticals EBITIonis Pharmaceuticals Net Income
2029e2.44 B undefined618.13 M undefined659.13 M undefined
2028e1.85 B undefined164.32 M undefined215.5 M undefined
2027e1.37 B undefined-151.51 M undefined-120.15 M undefined
2026e929.58 M undefined-420.84 M undefined-462.55 M undefined
2025e757.33 M undefined-531.37 M undefined-582.84 M undefined
2024e633.15 M undefined-535.05 M undefined-552.85 M undefined
2023787.65 M undefined-333.73 M undefined-366.29 M undefined
2022587.4 M undefined-410.2 M undefined-269.7 M undefined
2021810.5 M undefined-6.3 M undefined-28.6 M undefined
2020729.3 M undefined-141.8 M undefined-444.3 M undefined
20191.12 B undefined365.9 M undefined278.1 M undefined
2018599.7 M undefined-61.4 M undefined273.7 M undefined
2017514.2 M undefined31.1 M undefined300,000 undefined
2016372.8 M undefined-20.1 M undefined-60.4 M undefined
2015283.7 M undefined-75.8 M undefined-88.3 M undefined
2014214.2 M undefined-47.7 M undefined-39 M undefined
2013147.3 M undefined-51.7 M undefined-60.6 M undefined
2012102 M undefined-68.9 M undefined-65.5 M undefined
201199.1 M undefined-71.1 M undefined-84.8 M undefined
2010108.5 M undefined-46.9 M undefined-61.3 M undefined
2009121.6 M undefined-27.5 M undefined155.1 M undefined
2008107.2 M undefined-13.1 M undefined-18.2 M undefined
200758.3 M undefined-32.9 M undefined-141.6 M undefined
200614.9 M undefined-65.7 M undefined-45.9 M undefined
200540.1 M undefined-50.2 M undefined-72.4 M undefined
200442.6 M undefined-85.5 M undefined-142.9 M undefined

Ionis Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000.010.010.010.010.020.030.040.040.040.040.050.080.050.040.040.010.060.110.120.110.10.10.150.210.280.370.510.61.120.730.810.590.790.630.760.931.371.852.44
--500.0033.3325.0030.0023.0862.5038.4619.44-16.282.7843.2450.94-37.50-16.00-4.76-65.00314.2984.4813.08-10.74-8.333.0344.1245.5832.2431.4538.1716.5487.31-35.0311.11-27.5334.07-19.5719.5922.7247.1535.3331.73
-77,800.0012,966.679,725.007,780.005,984.624,862.502,992.312,161.111,809.302,161.112,102.701,467.92972.501,556.001,852.381,945.005,557.141,341.38727.10642.98-32.41785.86762.75529.25363.55274.91100.00100.0099.6799.6498.3598.6497.6198.86122.91102.7783.7556.9142.0531.92
000000000000000000000-0.04000000.370.510.61.120.720.80.570.78000000
-2-4-8-19-19-18-23-26-31-43-59-54-75-73-95-142-72-45-141-18155-61-84-65-60-39-88-600273278-444-28-269-366-552-582-462-120215659
-100.00100.00137.50--5.2627.7813.0419.2338.7137.21-8.4738.89-2.6730.1449.47-49.30-37.50213.33-87.23-961.11-139.3537.70-22.62-7.69-35.00125.64-31.82--1.83-259.71-93.69860.7136.0650.825.43-20.62-74.03-279.17206.51
5.46.510.412.915.719.521.525.626.526.928.73744.154.555.556.662.974.383.794.698.199.199.7100.6110.5117.7119.7120.9126.1134.1153.2139.6141141.8143.19000000
-----------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Ionis Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Ionis Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
19891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                                     
000.060.040.050.040.080.080.090.060.050.130.310.290.220.10.090.190.190.490.570.470.340.410.710.810.80.671.022.082.51.892.121.992.33
000000000.33.55.43.310.414.92.7103.92.44.94.110.91.26.90.511.13.911.41086312.86376.261.925.597.78
00000000000000000000000000000000000
000000000000011.1142.710.91.82.72.82.54.16.186.36.97.5108.618.22224.82228.43
0.10.11.82.11.61.61.61.72.10.90.92.66.44.87.496.69.69.520.58.17.15.48.77.515.714.814.873.1102.5139.8140.2143.4168.3184.45
000.060.040.060.050.080.080.090.060.060.130.330.320.240.130.110.210.210.520.60.480.360.420.740.840.840.81.172.212.722.132.352.22.64
0.729.51418.615.914.615.318.821.523.922.628.259.134.828.59.17.2617.427.335.796.691.186.28990.292.8121.9132.2166.3181.1196.1255.8242.94
0000000000712.55.60.61.45.30000000000000000000
00000000000000000000000000000000000
00.10.41.12.64.14.86.27.59.111.314.349.149.750.745.242.538.335.533.130.528.125.325.220.119.919.320.4222425.727.92900
00000000000000000000000000000000000
0.20.30.91.921.71.10.52.52.21.70.65.39.28.53.98.84.37.53.93.33.52.85.95.410.41.31.310.1303.7320.65041.675.3105.28
0.92.410.81723.221.720.52228.832.843.95088.2118.695.482.960.449.84954.461.167.3124.7122.2111.7119.3110.8114.5154459.9512.6259266.7331.1348.22
000.070.060.080.070.10.10.120.10.10.180.420.440.340.210.170.260.260.570.660.550.480.550.850.960.950.911.322.673.232.392.612.532.99
                                                                     
00000000001224.625.41414.70.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.14
0.010.010.080.080.110.120.170.180.190.190.250.350.580.60.60.620.770.880.830.960.9911.011.081.321.221.311.311.552.052.21.91.962.062.22
-2.5-7.2-16.1-35.6-54.7-72.8-96.5-123.1-154.1-197.1-256.8-311.5-386.6-459.9-555.6-698.4-770.8-816.8-827.7-851.2-696.2-756.7-841.5-907-967.6-1,006.6-1,094.9-1,181.4-1,241-967.3-707.5-1,131.3-1,159.9-1,429.6-1,795.91
00000000000.40.21.5-0.1-0.3-0.13.24.30.512.20.9-0.812.521.139.7-13.6-30.4-31.8-32-25.3-21.1-32.7-57.5-32.65
0000000.10.20.20.200.10.7-0.63.52.60000000000000000000
000.060.040.060.050.080.060.03-000.070.220.160.07-0.0700.0700.110.290.240.170.180.380.260.20.10.281.051.470.740.770.570.39
0.20.41.211.41.512.42.833.12.26.110.73.772.14.32.65.74.76.58.310.2111828.421.124.928.716.117.211.917.926.03
0.10.51.41.93.634.14.36.65.83.859.610.110.711.712.312.31416.419.519.227.823.334.342.844.260.291.877.6106.2155.9130196.5223.72
00.23.73.91.74.48.910.214.910.24.22.822.733.714.714.21.5138.4100.58374.536.635.948.151.767.351.3125.3160.3150.8109.797.896.8153.86
00000000000000000000000000000000000
0.10.312.24.92.456.22.33.63.94.69.821.416.510.57.87.57.22.14.35.63.44.94.42.991.21.613.70316.10.90.344.49
0.41.47.3911.611.31923.126.622.61514.648.275.945.643.423.725.162.2124.7111.5105.876.174.397.8115.4148.9133.8243.6280.3273.1598.9240.6311.5448.09
000.010.010.010.0100.020.060.080.090.10.130.190.210.240.140.130.160.130.140.150.220.220.230.450.460.590.610.630.770.621.231.181.23
00000000000000000000000000000000000
0.10.22.20000000002014.48.80.50023.5172.8107.151.321.966.7142.8127.8134.391.2108567.4505.3424371.4466.7925.8
000.010.010.010.0100.020.060.080.090.10.150.210.220.240.140.130.190.30.240.20.240.290.370.580.60.680.711.21.281.051.61.652.16
000.010.020.020.020.020.040.080.10.10.120.190.280.270.280.160.160.250.430.360.310.310.360.470.70.750.810.961.481.551.651.841.962.6
000.070.060.080.070.10.10.120.10.10.180.420.440.340.210.170.230.250.540.650.550.480.550.850.960.950.911.242.533.022.392.612.532.99
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Ionis Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Ionis Pharmaceuticals's financial health and stability.

Assets

Ionis Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Ionis Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Ionis Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Ionis Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-2-4-8-19-19-18-23-26-31-43-59-53-73-72-95-142-72-45-40-22150-61-84-65-60-39-88-60-10215287-479-28-269-366
0002332234556912129766991110991098121415171612
00000000000000000000000000000-2900341000
005-202526-7-9025-17-24-24-8253210-104-41-675086520-17737499-168-73-1137-77
00000-300111152535-14115210-171532-150423814396213718922529735846227671228
0000011123233391298864444566678996426
00000000000000000000137000000009250548
-2-3-1-19-15-15-15-21-19-34-48-23-6-94-95-101-61-5336212-108-63-111163621-1121746023453530-274-307
00-2-2-50-10-3-4-4-1-9-36-7-30-1-2-13-13-13-10-1-1-7-7-7-34-13-30-35-12-15-23
-10-4316-7-9-1-11-159-8-95-143-60-158347-32-55-234-2122310818-255-82-6056-358-929-41274194-262-214
00-4018-2-80-10-1113-3-93-134-23-78747-31-53-220-1983611819-254-75-5263-323-916-10309206-246-190
00000000000000000000000000000000000
000-12-2-21429110426120408-11-722430-429-8350-3-240970313-5086
5365037552973641182108144986216223439236232413205475141-38101649
5364-13935023361563122237129411237149431072024039227592411229475100-596245-55644
00000000000000000710401750000101480-138-558-169-11507
00000000000000000000000000000000000
1019-417-2033-91-107487-25-68-523632485-118-35-45935-16-14-4444149404-285471-592122
-2.5-3.7-4.4-21.5-20.5-16.1-16.2-22.1-23.4-39.2-52.9-24.8-15.5-131.2-103.1-105.3-61.4-54.233.8198.3-121.8-76.8-122.10.461.9-1.213.4-119.2139.3589.3314.70.818.8-290.1-331.32
00000000000000000000000000000000000

Ionis Pharmaceuticals stock margins

The Ionis Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ionis Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ionis Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ionis Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Ionis Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ionis Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ionis Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ionis Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ionis Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ionis Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ionis Pharmaceuticals Margin History

Ionis Pharmaceuticals Gross marginIonis Pharmaceuticals Profit marginIonis Pharmaceuticals EBIT marginIonis Pharmaceuticals Profit margin
2029e98.84 %25.36 %27.05 %
2028e98.84 %8.88 %11.65 %
2027e98.84 %-11.08 %-8.79 %
2026e98.84 %-45.27 %-49.76 %
2025e98.84 %-70.16 %-76.96 %
2024e98.84 %-84.51 %-87.32 %
202398.84 %-42.37 %-46.5 %
202297.6 %-69.83 %-45.91 %
202198.66 %-0.78 %-3.53 %
202098.35 %-19.44 %-60.92 %
201999.61 %32.59 %24.77 %
201899.7 %-10.24 %45.64 %
2017100 %6.05 %0.06 %
2016100 %-5.39 %-16.2 %
201598.84 %-26.72 %-31.12 %
201498.84 %-22.27 %-18.21 %
201398.84 %-35.1 %-41.14 %
201298.84 %-67.55 %-64.22 %
201198.84 %-71.75 %-85.57 %
2010-32.44 %-43.23 %-56.5 %
200998.84 %-22.62 %127.55 %
200898.84 %-12.22 %-16.98 %
200798.84 %-56.43 %-242.88 %
200698.84 %-440.94 %-308.05 %
200598.84 %-125.19 %-180.55 %
200498.84 %-200.7 %-335.45 %

Ionis Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Ionis Pharmaceuticals earnings per share therefore indicates how much revenue Ionis Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ionis Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ionis Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ionis Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ionis Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ionis Pharmaceuticals Revenue, EBIT and net profit per share

DateIonis Pharmaceuticals Sales per ShareIonis Pharmaceuticals EBIT per shareIonis Pharmaceuticals Earnings per Share
2029e15.43 undefined0 undefined4.17 undefined
2028e11.72 undefined0 undefined1.36 undefined
2027e8.66 undefined0 undefined-0.76 undefined
2026e5.89 undefined0 undefined-2.93 undefined
2025e4.8 undefined0 undefined-3.69 undefined
2024e4.01 undefined0 undefined-3.5 undefined
20235.5 undefined-2.33 undefined-2.56 undefined
20224.14 undefined-2.89 undefined-1.9 undefined
20215.75 undefined-0.04 undefined-0.2 undefined
20205.22 undefined-1.02 undefined-3.18 undefined
20197.33 undefined2.39 undefined1.82 undefined
20184.47 undefined-0.46 undefined2.04 undefined
20174.08 undefined0.25 undefined0 undefined
20163.08 undefined-0.17 undefined-0.5 undefined
20152.37 undefined-0.63 undefined-0.74 undefined
20141.82 undefined-0.41 undefined-0.33 undefined
20131.33 undefined-0.47 undefined-0.55 undefined
20121.01 undefined-0.68 undefined-0.65 undefined
20110.99 undefined-0.71 undefined-0.85 undefined
20101.09 undefined-0.47 undefined-0.62 undefined
20091.24 undefined-0.28 undefined1.58 undefined
20081.13 undefined-0.14 undefined-0.19 undefined
20070.7 undefined-0.39 undefined-1.69 undefined
20060.2 undefined-0.88 undefined-0.62 undefined
20050.64 undefined-0.8 undefined-1.15 undefined
20040.75 undefined-1.51 undefined-2.52 undefined

Ionis Pharmaceuticals business model

Ionis Pharmaceuticals is a biotechnology company specializing in the development and marketing of RNA-based therapeutics for the treatment of various diseases. The company was founded in 1989 and is headquartered in Carlsbad, California. Ionis Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Ionis Pharmaceuticals SWOT Analysis

Strengths

Ionis Pharmaceuticals Inc. benefits from several strengths that contribute to its success in the pharmaceutical industry. These include:

  • Strong Research and Development (R&D) capabilities, with a focus on innovative drug discovery and development.
  • Extensive intellectual property portfolio, providing Ionis Pharmaceuticals with a competitive advantage and protection for its novel therapies.
  • Collaborative partnerships with various pharmaceutical companies, enabling Ionis to leverage its technology and expand its market reach.
  • Proven track record of successful drug approvals and commercialization, demonstrating the company's ability to deliver effective treatments to patients.

Weaknesses

Despite its strengths, Ionis Pharmaceuticals Inc. also faces certain weaknesses that may hinder its growth and performance. These include:

  • Reliance on a limited number of key partnerships for revenue generation, making Ionis vulnerable to the uncertainties and decisions of its partners.
  • High research and development costs, which can strain the company's financial resources and profitability.
  • Limited international presence and dependence on the U.S. market, exposing Ionis to geopolitical and regulatory risks.

Opportunities

Ionis Pharmaceuticals Inc. can capitalize on various opportunities to further enhance its market position and growth prospects. These include:

  • Increasing demand for innovative therapies in areas of high unmet medical needs, such as rare diseases and genetic disorders.
  • Expanding partnerships with pharmaceutical companies to access additional resources, expertise, and funding for research and development.
  • Growing global healthcare expenditure, creating opportunities for market expansion and revenue growth.
  • Rapid advancements in genomics and personalized medicine, aligning with Ionis' expertise in antisense technology.

Threats

Ionis Pharmaceuticals Inc. faces several threats that could impact its business operations and future prospects. These threats include:

  • Intense competition from both established pharmaceutical companies and emerging biotech firms, increasing pressure on market share and pricing.
  • Stringent regulatory requirements and lengthy approval processes, leading to delays and uncertainties in bringing new drugs to market.
  • Risks associated with potential adverse events and safety concerns related to Ionis' drug candidates, affecting their market acceptance and commercial viability.
  • Currency exchange rate fluctuations, especially for international operations, introducing financial volatility and impacting profitability.

Ionis Pharmaceuticals Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Ionis Pharmaceuticals Revenue by Segment

Segmente20182017
Commercial254.92 M U001-
Revenue from the sale of medicines commercially as well as licensing and royalty revenues from other medicines, including SPINRAZA.--
Revenue from research and development services--
Revenue from research and development services performed under a collaboration agreement--
Research and Development Revenue Under Collaborative Agreements-107.14 M U001-

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Ionis Pharmaceuticals Revenue by Segment

Segmente20182017
SPINRAZA Royalties237.93 M U001-
ION582 is an antisense investigational medicine that targets Ubiquitin Protein Ligase E3A-Antisense Transcript (UBE3A-ATS), which is a long non-coding ribonucleic acid (lncRNA)--
IONIS-MAPT is an antisense drug designed to selectively reduce the production of microtubule-associated protein tau (MAPT), or tau protein, in the brain, for the treatment of Alzheimer's disease--
Royalty revenues from the sale of SPINRAZA (nusinersen)--

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Ionis Pharmaceuticals Revenue by Segment

Segmente20182017
Licensing and Other Royalties12 M U001-
An investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis (NASH)--
Revenue from license fees and other royalties, excluding royalties from the sale of SPINRAZA--

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Ionis Pharmaceuticals Revenue by Segment

Segmente20182017
ION532 (formerly IONIS-AZ5-2.5Rx ), also known as AZD2373, is an investigational antisense medicine designed to reduce the production of apolipoprotein L1 (APOL1) for the treatment of APOL1-associated chronic kidney disease (CKD). ION449 (formerly IONIS-AZ4-2.5-LRx), also known as AZD8233, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9)--
ION736, formerly known as IONIS-AZ7-2.5, is a Generation 2.5 antisense drug--

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Ionis Pharmaceuticals Revenue by Segment

Segmente20182017
Reportable segment in which the Company is exploiting a novel drug discovery platform created to generate a broad pipeline of first-in-class or best-in-class drugs for the Company and its partners. This segment generates revenue from a multifaceted partnering strategy. This strategy includes revenue from collaborations with preferred partners, traditional alliances and working with a consortium of companies that can exploit the Company's drugs and technology. Revenue from collaborations with preferred partners and traditional alliances may consist of upfront payments, milestone payments, licensing fees and royalties240.69 M U001-

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Ionis Pharmaceuticals Revenue by Segment

Segmente20182017
Reportable segment in which the Company is exploiting a novel drug discovery platform created to generate a broad pipeline of first-in-class or best-in-class drugs for the Company and its partners. This segment generates revenue from a multifaceted partnering strategy. This strategy includes revenue from collaborations with preferred partners, traditional alliances and working with a consortium of companies that can exploit the Company's drugs and technology. Revenue from collaborations with preferred partners and traditional alliances may consist of upfront payments, milestone payments, licensing fees and royalties-506.86 M U001
Reportable segment which includes the operations of the Company's wholly-owned subsidiary, Akcea Therapeutics, Inc., which was formed to develop and commercialize drugs for cardiometabolic disorders64.87 M U001-
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Ionis Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Ionis Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Ionis Pharmaceuticals shares outstanding

The number of shares was Ionis Pharmaceuticals in 2023 — This indicates how many shares 143.19 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ionis Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ionis Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ionis Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ionis Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Ionis Pharmaceuticals.

Ionis Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-1.18 -0.95  (19.5 %)2024 Q3
6/30/2024-0.94 -0.45  (52.1 %)2024 Q2
3/31/2024-1.07 -0.98  (8.61 %)2024 Q1
12/31/2023-0.85 -0.06  (92.92 %)2023 Q4
9/30/2023-1.06 -1.03  (2.99 %)2023 Q3
6/30/2023-0.92 -0.6  (34.77 %)2023 Q2
3/31/2023-0.93 -0.87  (6.36 %)2023 Q1
12/31/2022-0.94 -1.36  (-44.37 %)2022 Q4
9/30/2022-0.76 -0.33  (56.43 %)2022 Q3
6/30/2022-0.64 -0.74  (-16.37 %)2022 Q2
1
2
3
4
5
...
11

Eulerpool ESG Scorecard© for the Ionis Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

63/ 100

🌱 Environment

36

👫 Social

99

🏛️ Governance

55

Environment

Scope 1 - Direct Emissions
2,566
Scope 2 - Indirect emissions from purchased energy
2,052
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
4,618
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees53.5
Percentage of women in management
Percentage of Asian employees25
Share of Asian management
Percentage of Hispanic/Latino employees10
Hispano/Latino Management share
Percentage of Black employees3
Black Management Share
Percentage of white employees58
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Ionis Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
13.86625 % Fidelity Management & Research Company LLC21,894,80632,0716/30/2024
8.75083 % The Vanguard Group, Inc.13,817,568414,0176/30/2024
8.00487 % T. Rowe Price Investment Management, Inc.12,639,684-677,4286/30/2024
5.23143 % Bellevue Asset Management AG8,260,434-39,0806/30/2024
5.04515 % BlackRock Institutional Trust Company, N.A.7,966,296433,9936/30/2024
4.16011 % Wellington Management Company, LLP6,568,808873,1096/30/2024
3.82884 % Capital Research Global Investors6,045,7313,809,5449/30/2024
2.65390 % State Street Global Advisors (US)4,190,50534,8416/30/2024
2.40158 % T. Rowe Price Associates, Inc.3,792,092423,1826/30/2024
2.18789 % Tweedy, Browne Company LLC3,454,67606/30/2024
1
2
3
4
5
...
10

Ionis Pharmaceuticals Executives and Management Board

Dr. Brett Monia

(61)
Ionis Pharmaceuticals Chief Executive Officer, Director (since 2009)
Compensation 7.3 M

Mr. Joseph Baroldi

(45)
Ionis Pharmaceuticals Executive Vice President, Chief Business Officer
Compensation 4.02 M

Mr. Patrick O'Neil

(49)
Ionis Pharmaceuticals Chief Legal Officer, General Counsel and Corporate Secretary
Compensation 3.92 M

Dr. Eric Swayze

(57)
Ionis Pharmaceuticals Executive Vice President - Research
Compensation 3.62 M

Ms. Elizabeth Hougen

(61)
Ionis Pharmaceuticals Chief Financial Officer, Executive Vice President - Finance
Compensation 2.49 M
1
2
3
4

Ionis Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Alnylam Pharmaceuticals Stock
Alnylam Pharmaceuticals
SupplierCustomer0,930,670,12-0,110,09-0,41
Biora Therapeutics Stock
Biora Therapeutics
SupplierCustomer0,930,70-0,25-0,65-0,320,78
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer0,880,920,40-0,39-0,57-0,76
PTC Therapeutics Stock
PTC Therapeutics
SupplierCustomer0,850,490,610,060,330,83
ProQR Therapeutics Stock
ProQR Therapeutics
SupplierCustomer0,800,84-0,31-0,69-0,31-0,15
Swedish Orphan Biovitrum Stock
Swedish Orphan Biovitrum
SupplierCustomer0,770,710,880,82-0,08-0,30
Achaogen, Inc. Stock
Achaogen, Inc.
SupplierCustomer0,740,24-0,300,240,07
AstraZeneca Stock
AstraZeneca
SupplierCustomer0,540,690,790,890,39-0,40
Bicycl Ther Sp ADS Stock
Bicycl Ther Sp ADS
SupplierCustomer0,480,37-0,43-0,73-0,76-0,77
ICON Stock
ICON
SupplierCustomer0,420,510,38-0,50-0,55-0,78
1
2

Most common questions regarding Ionis Pharmaceuticals

What values and corporate philosophy does Ionis Pharmaceuticals represent?

Ionis Pharmaceuticals Inc is a renowned biopharmaceutical company known for its commitment to scientific innovation and patient-centric solutions. The company's core values revolve around excellence, integrity, and collaboration. Ionis focuses on developing transformative RNA-targeted medicines to address a wide range of diseases with high unmet medical needs. With a strong corporate philosophy centered on rigorous scientific research, Ionis prioritizes the advancement of therapeutic solutions that improve patients' lives. Ionis Pharmaceuticals Inc's dedication to pioneering therapies and strategic partnerships underscores its mission to deliver novel treatments and drive positive healthcare outcomes.

In which countries and regions is Ionis Pharmaceuticals primarily present?

Ionis Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Ionis Pharmaceuticals achieved?

Ionis Pharmaceuticals Inc has achieved several significant milestones throughout its history. Notably, the company pioneered the development of antisense technology, a groundbreaking approach to target and modulate the production of disease-causing proteins. Ionis has successfully advanced multiple antisense therapies into clinical trials and gained regulatory approvals for several of its drugs. Additionally, the company has established numerous collaborations with leading biopharmaceutical companies, further validating its innovative drug discovery platform. Ionis Pharmaceuticals Inc continues to make strides in the field of RNA-targeted therapeutics, aiming to improve the lives of patients affected by various diseases.

What is the history and background of the company Ionis Pharmaceuticals?

Ionis Pharmaceuticals Inc, formerly known as Isis Pharmaceuticals Inc, is a renowned biotechnology company headquartered in Carlsbad, California. Established in 1989, Ionis specializes in discovering and developing RNA-targeted therapeutics for various diseases. The company's innovative antisense technology allows the targeting of specific genes to treat a wide range of medical conditions. Ionis is recognized for its industry-leading pipeline of drugs, focusing on areas such as cardiovascular, metabolic, and neurological disorders. With a strong commitment to advancing healthcare through groundbreaking research and development, Ionis Pharmaceuticals Inc has emerged as a prominent player in the biotech sector, consistently striving to improve patients' lives.

Who are the main competitors of Ionis Pharmaceuticals in the market?

The main competitors of Ionis Pharmaceuticals Inc in the market are Alnylam Pharmaceuticals, Biogen, and Moderna.

In which industries is Ionis Pharmaceuticals primarily active?

Ionis Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Ionis Pharmaceuticals?

The business model of Ionis Pharmaceuticals Inc. focuses on developing RNA-targeted drugs to treat various diseases. By harnessing the power of antisense technology, Ionis utilizes genetic information to create specific RNA-targeted therapies that can selectively modulate gene expression, preventing or treating diseases at the molecular level. Ionis collaborates with pharmaceutical partners worldwide to advance its drug candidates through clinical development and commercialization. With its extensive pipeline and groundbreaking platform, Ionis aims to revolutionize the treatment of genetic diseases and offer hope to patients in need.

What is the P/E ratio of Ionis Pharmaceuticals 2024?

The Ionis Pharmaceuticals P/E ratio is -9.48.

What is the P/S ratio of Ionis Pharmaceuticals 2024?

The Ionis Pharmaceuticals P/S ratio is 8.28.

What is the Quality Investing of Ionis Pharmaceuticals?

The Quality Investing for Ionis Pharmaceuticals is 4/10.

What is the revenue of Ionis Pharmaceuticals 2024?

The expected Ionis Pharmaceuticals revenue is 633.15 M USD.

How high is the profit of Ionis Pharmaceuticals 2024?

The expected Ionis Pharmaceuticals profit is -552.85 M USD.

What is the business model of Ionis Pharmaceuticals

Ionis Pharmaceuticals Inc is a leading company in the field of RNA-based therapeutics. Since its founding in 1989, the company has been working to develop and bring to market innovative and effective therapies for numerous diseases. Today, the company employs over 800 people and is headquartered in Carlsbad, California. The business model of Ionis Pharmaceuticals is based on the development and commercialization of RNA-based therapeutics. These are drugs that are made based on ribonucleic acids (RNA). RNA is an important component of cells and is needed for the translation of genetic information into proteins. In the case of diseases, a disrupted RNA metabolism can lead to severe illnesses. Ionis Pharmaceuticals focuses on this aspect in the development of therapeutics and uses RNA to specifically intervene in disease mechanisms and correct them. The company has developed a broad portfolio of therapeutics. One of the most successful products is Spinraza, a medication for the treatment of spinal muscular atrophy (SMA), a hereditary disease of the motor nervous system. Spinraza is the first approved RNA-based therapeutic and has enabled a significant breakthrough in the development of this technology. Other products that the company has in its pipeline target the treatment of diseases such as diabetes, cancer, Alzheimer's, and other neurological disorders. The business model of Ionis Pharmaceuticals includes various divisions. In addition to the development of RNA-based therapeutics, the company also conducts research and development in the field of antisense technology. This involves the use of short nucleotide sequences to reduce protein expression. Unlike RNA therapy, antisense technology utilizes DNA. Ionis Pharmaceuticals is a pioneer in this field and has already developed numerous drugs based on this technology. Another important area for the company is the licensing and commercialization of therapeutics to partner companies. Ionis Pharmaceuticals has entered into a variety of collaborations with major pharmaceutical companies such as Roche, GlaxoSmithKline, and AstraZeneca. In these partnerships, the company is responsible for the development and clinical testing of the therapeutics, while the partners are responsible for the production, marketing, and distribution of the products. This allows Ionis Pharmaceuticals to leverage its expertise in RNA technology while benefiting from the distribution networks and experiences of its partner companies. Overall, the business model of Ionis Pharmaceuticals is positioned in a promising and rapidly growing market. The use of RNA and antisense technologies opens up completely new possibilities for the development of effective therapeutics for numerous diseases. With a broad portfolio of already approved and in-development drugs, as well as a strong partnership strategy, Ionis Pharmaceuticals is well-positioned to continue operating successfully in this field.

What is the Ionis Pharmaceuticals dividend?

Ionis Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Ionis Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Ionis Pharmaceuticals or the company does not pay out a dividend.

What is the Ionis Pharmaceuticals ISIN?

The ISIN of Ionis Pharmaceuticals is US4622221004.

What is the Ionis Pharmaceuticals WKN?

The WKN of Ionis Pharmaceuticals is A2ACMZ.

What is the Ionis Pharmaceuticals ticker?

The ticker of Ionis Pharmaceuticals is IONS.

How much dividend does Ionis Pharmaceuticals pay?

Over the past 12 months, Ionis Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ionis Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Ionis Pharmaceuticals?

The current dividend yield of Ionis Pharmaceuticals is .

When does Ionis Pharmaceuticals pay dividends?

Ionis Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ionis Pharmaceuticals?

Ionis Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Ionis Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ionis Pharmaceuticals located?

Ionis Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ionis Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ionis Pharmaceuticals from 12/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/15/2024.

When did Ionis Pharmaceuticals pay the last dividend?

The last dividend was paid out on 12/15/2024.

What was the dividend of Ionis Pharmaceuticals in the year 2023?

In the year 2023, Ionis Pharmaceuticals distributed 0 USD as dividends.

In which currency does Ionis Pharmaceuticals pay out the dividend?

The dividends of Ionis Pharmaceuticals are distributed in USD.

All fundamentals about Ionis Pharmaceuticals

Our stock analysis for Ionis Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ionis Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.